Skip to main content
A quant shop's stocks and options workflow, simplified into one desk.

Screeners vs workflow

A screener can surface symbols. A workflow helps you inspect what matters.

Screeners are useful. They help traders narrow the market and find symbols worth a closer look. But a symbol is not a thesis, a backtest, a risk review, or a plan for what to watch next. PredictDesk is built for the research work that starts after a symbol gets your attention.

Discovery

Screeners are good at finding what matches a filter.

A screener can help a trader identify symbols or setups that meet visible criteria. That is useful, but it usually leaves the deeper research burden scattered across charts, notes, tests, and broker tools.

  • Use screeners to narrow the market, not to finish the decision.
  • Treat a matched filter as the start of research.
  • Keep the next question focused on evidence and tradeoffs.

Workflow

A research workflow keeps the setup and evidence connected.

PredictDesk is positioned around continuity: define the setup, inspect why it qualified, compare assumptions, review hypothetical behavior, and preserve the reasoning for later review.

  • Connect symbol discovery to diagnostics.
  • Keep assumptions visible while the review deepens.
  • Carry context forward instead of rebuilding it from memory.

Judgment

The point is better review, not a louder list.

More symbols do not automatically create a stronger process. The trader still needs to inspect what matters, challenge assumptions, and decide what deserves more attention.

  • Use workflow structure to reduce scattered review.
  • Make evidence easier to compare before capital is at risk.
  • Keep trader judgment at the center of the process.

Boundary

This is not a claim that workflows replace screeners

PredictDesk does not claim screeners are unnecessary or that any workflow guarantees better outcomes. It is a broker-agnostic research workflow for inspecting setups, not a trade recommendation service or execution venue.

Not a broker. Not investment advice. Backtests and scenario results are hypothetical. Options involve significant risk. Waitlist signup does not create approval or access.